Published in Vaccine Weekly, January 21st, 2009
"Recently, the vaccine also received approval for the prevention of vulvar and vaginal cancers in women aged 9 to 26 years. Although Guillain-Barre syndrome and death have been reported in women who received the vaccine, an analysis of available data by the US Food and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly